AptarGroup reported reported sales of $963 million for the quarter ended December 31, 2025, a 14% increase over the prior year period, with core sales up 5%. Reported net income declined 26% to $74 million, reflecting higher production costs and mix shifts, while adjusted earnings per share were $1.25, narrowly surpassing the Zacks Consensus Estimate of $1.24 and compared with adjusted EPS of $1.62 in the year-ago quarter at comparable exchange rates.

All three operating segments delivered core sales growth in Q4. Pharma sales rose 10% on a reported basis (core +4%), driven by a 24% increase in injectables—led by GLP-1 elastomeric components—and double-digit growth in nasal drug delivery; Beauty achieved reported growth of 24% (core +10%) on strong demand for fragrance dispensers, hair, body and sun care applications; Closures reported 5% sales growth (core +1%), fueled by higher volumes despite headwinds from lower resin pricing.

During the quarter, Aptar returned $206 million to investors through dividends and share repurchases, repurchasing 1.5 million shares at a cost of $175 million. The Board approved a new authorization for up to $600 million in additional share repurchases. At year-end, the company held $410 million in cash and short-term investments against $1.07 billion in net debt, maintaining a leverage ratio of 1.38x and ending capital expenditures at approximately 7% of sales.

For Q1 2026, Aptar expects adjusted EPS between $1.13 and $1.21, assuming an effective tax rate of 21.0%–23.0% and a €1.18/USD exchange rate. The company forecasts 2026 capital investments of $260 million to $280 million. Management anticipates continued Pharma growth outside emergency medicine, early strength in prestige fragrance for Beauty, and steady performance in Closures, supported by innovation, productivity initiatives and a strong balance sheet.